Phathom Pharmaceuticals, Inc.PHATNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +4249.56% | +1391.58% | +439.36% | +202.74% |
| Gross Profit Growth | +0.00% | +7733.03% | +1568.57% | +479.44% | +209.47% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +13.82% | +24.00% | +23.29% | +23.75% | +13.57% |
| Weighted Average Shares Diluted Growth | +13.82% | +24.00% | +23.29% | +23.75% | +13.57% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +2270.01% | +837.46% | +371.22% | +165.01% |
| Inventory Growth | +2702.70% | +165.56% | +117.15% | +57.60% | +16.07% |
| Asset Growth | +63.32% | -8.55% | -17.47% | -21.65% | -37.92% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +129.24% | +299.16% | +20.38% | +13.45% | -99.48% |
| R&D Expense Growth | -29.11% | -35.91% | -2.61% | +23.05% | -19.16% |
| SG&A Expenses Growth | +226.96% | +34.98% | +52.35% | +12.44% | -32.25% |